NCT01488734

Brief Summary

The purpose of this study is to compare the safety and efficacy of two different amounts of vitamin D2 (600 or 4000 International Units/day) provided by mushrooms added to one of the daily meals versus same doses of vitamin D3 provided as oral supplements sold in any drugstore in reaching adequate or optimal blood levels of 25(OH)D in people with Vitamin D deficiency and pre-diabetes (high blood sugar without full blown diabetes) or the metabolic syndrome. Metabolic syndrome is the name of a group of risk factors that raise the risk for heart disease and other health problems, such as diabetes and stroke as described by the US department of Health and Human Services. This study will also attempt to demonstrate and compare the effect of the intervention with above two doses of vitamin D on blood levels of tests that show inflammation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
47

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2011

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2011

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

December 6, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 8, 2011

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2013

Completed
Last Updated

April 14, 2017

Status Verified

April 1, 2017

Enrollment Period

1.8 years

First QC Date

December 6, 2011

Last Update Submit

April 12, 2017

Conditions

Keywords

Vitamin DMushroomCholecalciferolPrediabetesMetabolic Syndrome

Outcome Measures

Primary Outcomes (1)

  • 25OH Vitamin D level

    To compare the efficacy of two different doses of vitamin D2 (600 or 4000 IU/day) provided by Vitamin D2 fortified mushrooms added to one of the daily meals versus same doses of vitamin D3 provided as oral supplements in reaching adequate or optimal circulating levels of 25(OH) D in a racially diverse group of subjects with Vitamin D deficiency and pre-diabetes or the metabolic syndrome.

    at 4 months

Secondary Outcomes (5)

  • Serum calcium

    at 1 month

  • Serum calcium

    at 2 months

  • Serum calcium

    at 3 months

  • Serum calcium

    at 4 months

  • Markers of inflammation and metabolic control

    at 4 months

Study Arms (4)

Mushroom with 600 IU vitamin D2

EXPERIMENTAL

Mushroom with 600 IU of vitamin D2 daily and placebo tablet

Dietary Supplement: Mushroom with 600 IU vitamin D2Drug: Placebo

Mushroom with 4000 IU Vitamin D2

EXPERIMENTAL

Mushroom with 4000 IU of Vitamin D2 daily and placebo tablet

Dietary Supplement: Mushroom with 4000 IU Vitamin D2Drug: Placebo

600 IU Vitamin D3 and untreated mushroom

ACTIVE COMPARATOR

Commercially available tablets with 600 IU/day of Vitamin D3 and untreated mushroom

Dietary Supplement: 600 IU Vitamin D3 and untreated mushroom

4000 IU Vitamin D3 and untreated mushroom

ACTIVE COMPARATOR

Commercially available tablets with 4000 IU/day of Vitamin D3 and untreated mushroom

Dietary Supplement: 4000 IU Vitamin D3 and untreated mushroom

Interventions

Subjects in this group will eat daily meals containing mushrooms fortified with 600 IU of Vitamin D2. These subjects will also take one placebo tablet per day.

Mushroom with 600 IU vitamin D2

Subjects in this group will eat daily meals containing mushrooms fortified with 4000 IU of Vitamin D2. These subjects will also take one placebo tablet per day.

Mushroom with 4000 IU Vitamin D2

Subjects in this group will take one commercially available tablet of 600 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.

600 IU Vitamin D3 and untreated mushroom

Subjects in this group will take one commercially available tablet of 4000 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.

4000 IU Vitamin D3 and untreated mushroom

Placebo for the fortified mushroom arms

Mushroom with 4000 IU Vitamin D2Mushroom with 600 IU vitamin D2

Eligibility Criteria

Age30 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult non-smoking subjects from ages 30 to 90, any race or gender
  • Presence of at least two of the following characteristics:
  • Waist circumference:
  • Men: \> 102 cm Women: \> 88 cm
  • Blood pressure: \> 130/85 mm Hg (or use of anti-BP medication)
  • HDL-cholesterol:
  • Men: \< 40 mg/dL Women: \< 50 mg/dL
  • Triglycerides: \> 150 mg/dL (or use of medications for high triglycerides such as fibrates or nicotinic acid)
  • Fasting blood sugar \> 100 mg/dl (or use of metformin), but a HbA1c \< 6.5%

You may not qualify if:

  • Blood levels of 25(OH)D \> 50 nmol/L
  • Regular intake of vitamin D fortified milk exceeding approximately 3 glasses/day
  • Lack of the ability to comprehend instructions and/or sign the consent form
  • Inability to comply with the potential requirement to eat a daily portion of provided mushroom together with meals
  • Inability to comply with the rule of avoiding any beach days during the duration of the study
  • Any projected trip to sunny places such as Puerto Rico and the Caribbean during the period of study
  • Any attendance to tanning studios during the period of study
  • Women who regularly use a veil over their heads
  • Any history of kidney stone formation
  • Non-traumatic bone fracture over the past 3 years
  • Any form of vitamin D supplement intake, including combined calcium and vitamin D products
  • Active smoking

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States

Location

MeSH Terms

Conditions

Vitamin D DeficiencyMetabolic SyndromePrediabetic State

Interventions

ErgocalciferolsCholecalciferol

Condition Hierarchy (Ancestors)

AvitaminosisDeficiency DiseasesMalnutritionNutrition DisordersNutritional and Metabolic DiseasesInsulin ResistanceHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesDiabetes MellitusEndocrine System Diseases

Intervention Hierarchy (Ancestors)

CholestenesCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSterolsVitamin DSecosteroidsMembrane LipidsLipids

Study Officials

  • Jaime Uribarri, MD

    Icahn School of Medicine at Mount Sinai

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 6, 2011

First Posted

December 8, 2011

Study Start

November 1, 2011

Primary Completion

September 1, 2013

Study Completion

September 1, 2013

Last Updated

April 14, 2017

Record last verified: 2017-04

Locations